CRIS Current Research Information System

PILERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.230
EU - Europa 12.200
AS - Asia 4.522
AF - Africa 712
SA - Sud America 33
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 13
Totale 34.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.171
GB - Regno Unito 4.086
CN - Cina 1.928
DE - Germania 1.707
SE - Svezia 1.584
IT - Italia 1.315
VN - Vietnam 1.306
UA - Ucraina 1.006
IN - India 785
FR - Francia 550
RU - Federazione Russa 524
IE - Irlanda 485
ZA - Sudafrica 346
EE - Estonia 299
CH - Svizzera 220
SG - Singapore 194
TG - Togo 137
CI - Costa d'Avorio 99
FI - Finlandia 74
SC - Seychelles 73
HR - Croazia 71
JO - Giordania 68
BG - Bulgaria 61
GR - Grecia 60
BE - Belgio 56
IR - Iran 55
CA - Canada 54
JP - Giappone 53
NG - Nigeria 43
LB - Libano 33
NL - Olanda 23
BR - Brasile 21
TR - Turchia 19
EU - Europa 17
HK - Hong Kong 14
UZ - Uzbekistan 12
KR - Corea 11
PL - Polonia 11
ES - Italia 10
PT - Portogallo 10
RO - Romania 9
AT - Austria 8
AU - Australia 8
CL - Cile 7
CZ - Repubblica Ceca 7
IQ - Iraq 6
A2 - ???statistics.table.value.countryCode.A2??? 5
DK - Danimarca 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PH - Filippine 5
ET - Etiopia 4
IL - Israele 4
LU - Lussemburgo 4
PE - Perù 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
TN - Tunisia 4
BD - Bangladesh 3
HU - Ungheria 3
MX - Messico 3
AL - Albania 2
CU - Cuba 2
EG - Egitto 2
ID - Indonesia 2
KW - Kuwait 2
NO - Norvegia 2
SA - Arabia Saudita 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
DZ - Algeria 1
GE - Georgia 1
GH - Ghana 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
TW - Taiwan 1
Totale 34.732
Salva come PNG Salva come JPEG
Città #
Southend 3.699
Fairfield 2.741
Ashburn 1.413
Woodbridge 1.379
Chandler 1.266
Houston 1.248
Wilmington 1.201
Seattle 1.190
Cambridge 981
Princeton 882
Ann Arbor 813
Dong Ket 694
Jacksonville 638
Dublin 485
Nanjing 403
Westminster 382
Padova 371
Berlin 226
Saint Petersburg 204
Bern 192
Bologna 188
Jinan 182
Shenyang 162
Mülheim 146
Nanchang 143
San Diego 141
Lomé 137
Hebei 133
Singapore 132
New York 120
Changsha 113
Bremen 112
Milan 101
Abidjan 99
Beijing 98
Tianjin 93
Boardman 88
Jiaxing 85
Medford 70
Mahé 69
Amman 68
Helsinki 68
Sofia 61
Dearborn 60
Norwalk 55
Turin 55
Hangzhou 54
Redwood City 54
Zhengzhou 54
Ningbo 53
Brussels 52
Falls Church 50
Olalla 49
San Venanzo 49
Haikou 47
Taizhou 46
Tokyo 46
Hyderabad 45
Abeokuta 42
Des Moines 40
Redmond 40
Verona 40
Guangzhou 37
Los Angeles 37
Taiyuan 34
Lanzhou 33
Toronto 33
Bühl 25
Frankfurt am Main 24
Fremont 24
Chicago 22
Kunming 22
Paris 22
Florence 21
Fuzhou 21
Pune 20
Rome 20
Frankfurt Am Main 19
London 19
Leawood 18
Hefei 16
Istanbul 16
Moscow 16
Andover 14
Lausanne 14
Monmouth Junction 13
San Francisco 13
Zanjan 13
Buffalo 12
Ardabil 10
Phoenix 10
São Paulo 10
Wayne 10
Plauen 9
Rijeka 9
Athens 8
Kuban 8
Reggio Emilia 8
Sacramento 8
Salsomaggiore Terme 8
Totale 24.624
Salva come PNG Salva come JPEG
Nome #
Biology and treatment of follicular lymphoma. 195
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 182
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 180
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 178
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 177
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 175
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 173
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 168
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 166
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 159
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 157
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 155
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 149
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 148
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 146
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 146
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 145
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 145
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 143
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 143
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 142
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 141
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 140
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 139
Expression of CD52 in peripheral T-cell lymphoma. 138
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 137
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 135
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 135
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 134
CD30 expression in peripheral T-cell lymphomas 134
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 134
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 134
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 133
IFI16 expression is related to selected transcription factors during B-cell differentiation 133
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 132
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 132
Anaplastic Large Cell Lymphoma: a critical reappraisal 129
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 128
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 128
BCL10 down-regulation in peripheral T-cell lymphomas. 128
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 127
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 126
B-cells and mixed cryoglobulinemia. 126
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 126
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 126
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 125
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 125
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 125
Histopathology of B-cell chronic lymphocytic leukemia. 123
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 123
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 123
Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. 122
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 121
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 121
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 120
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. 119
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 119
Pathobiology of hodgkin lymphoma. 119
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. 118
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 118
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 117
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 117
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 117
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 117
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 116
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 116
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. 115
Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. 115
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 115
Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. 114
Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. 114
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 114
Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. 114
Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? 113
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 113
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 113
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 113
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 112
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 112
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. 112
Molecular genetics of peripheral T-cell lymphomas 112
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 111
Aberrant promoter methylation of multiple genes thoughout the clinico-pathologic spectrum of B-cell neoplastia. 111
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 111
HIV infection and c-MYC status in endemic Burkitt lymphoma 111
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 111
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK(+) ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project 111
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. 110
Targeted molecular therapy in peripheral T-cell lymphomas 110
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 110
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 110
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 110
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 110
High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. 109
Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. 109
T-Cell Lymphomas in South America and Europe 109
Simple diagnostic assay for hairy cell leukemia by cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 108
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 107
Totale 12.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.821 0 281 146 748 1.146 1.190 1.442 1.497 1.525 712 424 710
2020/20215.375 1.159 413 150 231 131 336 59 286 508 286 259 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.590 89 290 108 174 142 290 109 94 48 128 54 64
2024/2025220 217 3 0 0 0 0 0 0 0 0 0 0
Totale 35.463